Emgality®: a migraine treatment that can fit into your patient’s life1

    View additional data for patients with migraine, including results from a 12-month, open-label safety study

    References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:644-655. 3. Silberstein SD, Holland S, Freitag F, et al. Correction: Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2013;80:871. 4. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18. 5. Data on File. Lilly USA, LLC. DOF-GZ-US-0085. 6. Data on File. Lilly USA, LLC. DOF-GZ-US-0120. 7. Data on File. Lilly USA, LLC. DOF-GZ-US-0013. 8. Data on File. Lilly USA, LLC. DOF-GZ-US-0020. 9. Data on File. Lilly USA, LLC. DOF-GZ-US-0060. 10. Data on File. Lilly, USA, LLC. DOF-GZ-US-0181. 11. Data on File. Lilly USA, LLC. DOF-GZ-US-0111. 12. Data on File. Lilly, USA, LLC. DOF-GZ-US-0180. 13. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. 14. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. 15. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. 16. Data on File. Lilly USA, LLC. DOF-GZ-US-0107. 17. Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. doi:10.1186/s12883-018-1193-2. 18. Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20:90. doi:10.1186/s12883- 020-1609-7. 19. Data on File. Lilly USA, LLC. DOF-GZ-US-0137. 20. Data on File. Lilly USA, LLC. DOF-GZ-US-0139.

    INDICATIONS

    Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

    • Preventive treatment of migraine
    • Treatment of episodic cluster headache

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS
    Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

    WARNINGS AND PRECAUTIONS
    Hypersensitivity Reactions
    Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

    ADVERSE REACTIONS
    The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

    Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

    GZ HCP ISI 10DEC2019